Statements (59)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:drug
|
gptkbp:bfsLayer |
3
|
gptkbp:bfsParent |
gptkb:temple
gptkb:Glaxo_Smith_Kline |
gptkbp:activities |
anti-inflammatory and bronchodilator effects
|
gptkbp:appointed_by |
inhalation
|
gptkbp:approves |
gptkb:2019
|
gptkbp:availability |
prescription only
|
gptkbp:clinical_trial |
Phase III
asthma management COPD management studied in clinical trials |
gptkbp:contains |
gptkb:budesonide
gptkb:formoterol |
gptkbp:contraindication |
hypersensitivity to components
|
gptkbp:dosage_form |
aerosol
|
gptkbp:duration |
long-term use
|
gptkbp:effective_date |
FDA approved
|
gptkbp:formulation |
combination therapy
|
https://www.w3.org/2000/01/rdf-schema#label |
Breztri Aerosphere
|
gptkbp:indication |
maintenance treatment of COPD
|
gptkbp:ingredients |
gptkb:budesonide
gptkb:formoterol_fumarate |
gptkbp:interacts_with |
MAO inhibitors
diuretics beta-blockers |
gptkbp:invention |
patented
|
gptkbp:is_effective_against |
improves quality of life
improves lung function reduces exacerbations |
gptkbp:is_used_for |
chronic obstructive pulmonary disease
|
gptkbp:label |
prescribing information available
|
gptkbp:manager |
inhalation
|
gptkbp:manufacturer |
gptkb:temple
|
gptkbp:marketed_as |
gptkb:Breztri
multiple countries |
gptkbp:packaging |
pressurized metered-dose inhaler
|
gptkbp:pharmacokinetics |
excreted in urine
metabolized in the liver systemic absorption |
gptkbp:population |
adults
children over 12 years |
gptkbp:price |
varies by region
|
gptkbp:provides_information_on |
included in COPD treatment guidelines
included in asthma treatment guidelines |
gptkbp:research |
ongoing studies for new indications
|
gptkbp:safety_features |
generally well tolerated
|
gptkbp:side_effect |
gptkb:healthcare_organization
dizziness fatigue headache nausea cough sinusitis throat irritation upper respiratory tract infection oral thrush |
gptkbp:storage |
store at room temperature
|
gptkbp:type_of_care |
important for effectiveness
|